Biosimilars: a position paper of the European Society for Medical Oncology, with particular reference to oncology prescribers.
Fiche du document
2016
- doi: 10.1136/esmoopen-2016-000142
- issn: 2059-7029
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/doi/10.1136/esmoopen-2016-000142
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pmid/28848668
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pissn/2059-7029
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/urn/urn:nbn:ch:serval-BIB_765C8EC0B78B7
info:eu-repo/semantics/openAccess , Copying allowed only for non-profit organizations , https://serval.unil.ch/disclaimer
Sujets proches
Health care delivery Health services Personal health services Medical services Medical and health care industry Delivery of medical care Health care Healthcare Delivery of health careCiter ce document
J. Tabernero et al., « Biosimilars: a position paper of the European Society for Medical Oncology, with particular reference to oncology prescribers. », Serveur académique Lausannois, ID : 10.1136/esmoopen-2016-000142
Métriques
Partage / Export
Résumé
Biosimilars present a necessary and timely opportunity for physicians, patients and healthcare systems. If suitably developed clinically, manufactured to the correct standards and used appropriately, they can positively impact on the financial sustainability of healthcare systems. A critical consideration regarding the introduction of biosimilars into the clinic centres on the required information concerning all the respective procedures. This position paper aims to describe the issues revolving around biosimilars that are relevant to the field of oncology, especially the prescribers. More specifically, we discuss aspects related to definition, forms of biosimilars, labelling, extrapolation, interchangeability, switching, automatic substitution, clinical standards on safety and efficacy, responsibilities among prescribers and pharmacists, potential impact on financial burden in healthcare and the current scenario and future prospects of biosimilars in Europe and the rest of the world.